Efficacy of Abrocitinib and Dupilumab on Chronic Hand Eczema in Patients with Moderate-to-Severe Atopic Dermatitis: A Prespecified Exploratory Analysis of the Phase 3 JADE DARE Study
Authors: Robert Bissonnette, Vivian Shi, Ana Giménez-Arnau, Marie-Noëlle Crépy, Marie L A Schuttelaar, Irina Lazariciu, Tamara Bratt, Andrew Selfridge, Gerardo Encinas, Herwig Koppensteiner Read more on pubmed
Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials
Authors: Mark G Lebwohl, Melinda Gooderham, Richard B Warren, Lawrence F Eichenfield, Jessica H Rubens, Tracy Cardillo, Christopher Russo, Cynthia M C DeKlotz, Megan Miller-Kassamali, Luis Anaya Velarde, Ming-Chun Hsu, Shu Li, Ya-Wen Yang, Sarah Ofori, Robert Bissonnette, Jennifer Soung, Adelaide A Hebert, Linda Stein Gold Read more on pubmed
EP262, an MRGPRX2 Antagonist for the Treatment of Atopic Dermatitis: Results From the Phase 2 Randomized EASE Study
Authors: Dehn, S., Cooper, D., Weyer, C., Ferguson, B., Srinivasan, S., Saint-Cyr Proulx, E., & Bissonnette, R. Read more on pubmed
Placebo Response in Randomised Controlled Trials of Systemic Therapies for Cutaneous Lupus Erythematosus: A Systematic Review and Meta-Analysis
Authors: LĂ©garĂ©, S., Lin, S., Vahey, S., Ovalles-Bonilla, J. G., D’Angelo, P., Jankicevic, J., & Bissonnette, R. Read more on pubmed
Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials
Authors: Linda Stein Gold, April W Armstrong, Jennifer Soung, Ronald B Vender, Ălvaro GonzĂĄlez Cantero, Matthias Hoffmann, Scott T Guenthner, H Chih-Ho Hong, Dedee F Murrell, Eingun James Song, Leon Kircik, Matthias Augustin, Maxwell Sauder, Sascha Gerdes, Ofelia Reyes-Servin, Bassey Effiom Edem, Jennifer Campbell, Kellen Cresswell, Lea Kephart, Shu Li, Ya-Wen Yang, Robert Bissonnette Read […]
Ruxolitinib Cream Demonstrated Rapid Reductions in Itch and Atopic Dermatitis Signs That Correlated With Biomarkers
Authors: Bissonnette, R., Saint-Cyr Proulx, E., Correa da Rosa, J., Estrada, Y., Ren, H., Nawaz, H., Halden, P., Stefani-Hunyady, D., Popovic, K., Volkova, A., Smith, S. H., & Guttman-Yassky, E. Read more on pubmed
Characterizing the Burden of Hand Dermatitis in Canada: A Cross-Sectional Survey of Disease Impact
Authors: Cresswell-Melville, A., Mehta, S., Metko, D., Bissonnette, R., & Molin, S. Read more on pubmed
Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings
Authors: Warren, R. B., Gooderham, M., Lain, E., Bissonnette, R., Huang, Y. H., Ringuet, J., Hoffmann, M., Pinter, A., Merola, J. F., Rubens, J. H., Fan, D., Hsu, M. C., Li, S., Yang, Y. W., DeKlotz, C. M. C., & Song, E. J. Read more on pubmed
Maintenance of Response With Icotrokinra, a Targeted Oral Peptide, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Randomized Treatment Withdrawal in Adults From the Phase 3, ICONIC-LEAD Study
Authors: Soung, J., Cui, Y., Bissonnette, R., Lebwohl, M. G., GonzĂĄlez-Cantero, Ă., Pinter, A., Rich, P., Prajapati, V. H., Miller-Kassamali, M., Cafone, J., Jiang, J., Li, S., Yang, Y. W., & Pink, A. E. Read more on pubmed
International Eczema Council Definitions of Low Disease Activity and Remission in Atopic Dermatitis: A Consensus Statement
Innovaderm/Indero founder Dr. Robert Bissonnette has coauthored the International Eczema Councilâs globally endorsed, expert-derived framework defining low disease activity and remission in atopic dermatitis, in JAMA Dermatology, April 2026. These standardized, clinically meaningful definitions provide a foundation for harmonized trial design, regulatory evaluation, and longitudinal comparative effectiveness research. Authors: Merola, J. F., Childs, B. A., Bartley, B. R., Bissonnette, R., Bieber, T., Guttman-Yassky, E., Paller, A. S., […]
